Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
27 hedge funds and large institutions have $17.4M invested in Interpace Biosciences, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 3 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
4% less funds holding
Funds holding: 28 → 27 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
47% less capital invested
Capital invested by funds: $32.9M → $17.4M (-$15.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
+$58.8K |
| 2 |
Renaissance Technologies
New York
|
+$55.8K |
| 3 |
ANTB
AMG National Trust Bank
Greenwood Village,
Colorado
|
+$50.1K |
| 4 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$36.7K |
| 5 |
MA
Minerva Advisors
Bala Cynwyd,
Pennsylvania
|
+$29.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
-$601K |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$482K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$54.1K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$32.7K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$7.68K |
IDXG Hedge Fund Activity: Q3 2014 in Review
27 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q3 2014, worth a combined $17.4M — down 47% from $32.9M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of IDXG and 2 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 9 added.
The largest buyer was Shepherd Kaplan Krochuk, adding an estimated $58.8K. The largest seller was Royce & Associates, cutting an estimated $601K.
- 27 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q3 2014, down from 28 in Q2 2014.
- Funds reported $17.4M of Interpace Biosciences, Inc. Common Stock stock for Q3 2014, down 47% quarter-over-quarter.
- 2 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q3 2014 and 3 closed out, a net change of -1 holder.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q3 2014 was Shepherd Kaplan Krochuk, an estimated $58.8K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q3 2014 was Royce & Associates, an estimated $601K sold.
Based on aggregated 13F filings for Q3 2014.